Journal of Population Therapeutics & Clinical Pharmacology

REVIEW ARTICLE
DOI: 10.53555/jptcp.v30i16.4754

PHARMACOKINETICS OF LIPANTHYL IN THE ELDERLY

Obaidallah Abdullah Almuzini[1]*, Ali Ahmed Alzubaidi[2], Darwish Ahmed Alharbi[3], Mohammed Ahmed Alqarni[4], Jabril Ali Mansour Dahhas[5], Faleh Saleh Mohamed Alyami[6]

[1*]Pharmacist, oal-muzini@moh.gov.sa, Eradah and mental health complex-Eradah service
[2]Pharmacist, alahalzubaidi@moh.gov.sa, King Fahad General Hospital in Jeddah.
[3]Pharmacy technician, Darwisha@moh.gov.sa, Eradah and mental health complex-Eradah service
[4]Pharmacy technician, Malqarni32@moh.gov.sa, Eradah and mental health complex-Eradah service.
[5]Pharmacy technician, JDAHHAS@moh.gov.sa, eradah mental health in Al-Kharj
[6]Pharmacy technician, falyami22@moh.gov.sa, eradah mental health in Al-Kharj

***Corresponding Author:** Obaidallah Abdullah Almuzini
*Pharmacist, oal-muzini@moh.gov.sa, Eradah and mental health complex-Eradah service

Abstract :
Lipanthyl, also known as fenofibrate, is a lipid-lowering medication commonly used in the elderly population to manage dyslipidemia. Understanding the pharmacokinetics of Lipanthyl in the elderly is crucial for optimizing medication dosing and minimizing adverse effects. This essay aims to review the pharmacokinetics of Lipanthyl in the elderly, focusing on absorption, distribution, metabolism, and excretion. Additionally, the potential effects of aging on Lipanthyl pharmacokinetics will be discussed .

Keywords: Lipanthyl, fenofibrate, pharmacokinetics, elderly, dyslipidemia

Introduction:

Dyslipidemia is a common condition among the elderly population, characterized by abnormal levels of lipids in the blood. Lipanthyl, a fibric acid derivative, is commonly prescribed to manage dyslipidemia by reducing triglyceride and LDL cholesterol levels while increasing HDL cholesterol levels. Despite its widespread use, the pharmacokinetics of Lipanthyl in the elderly remain poorly understood .

Lipanthyl, also known as fenofibrate, is a medication commonly used for the treatment of dyslipidemia, a condition characterized by abnormal levels of lipids (cholesterol and triglycerides) in the blood. Pharmacokinetics refers to how the body processes a drug, including its absorption, distribution, metabolism, and elimination. When considering the pharmacokinetics of Lipanthyl in the elderly, several factors should be taken into account:

Absorption: The absorption of Lipanthyl is not significantly affected by age. It is well absorbed from the gastrointestinal tract, and the rate and extent of absorption are generally consistent across different age groups.

Distribution: Lipanthyl is extensively bound to plasma proteins, primarily albumin. Age-related changes in protein binding may potentially affect the distribution of the drug in the elderly. However, the clinical significance of this alteration is not well-established.

Metabolism: Lipanthyl is primarily metabolized in the liver via various enzymatic pathways, including glucuronidation and oxidation. Age-related changes in liver function can impact the metabolism of drugs. In the elderly, there may be a slight decrease in the metabolism of Lipanthyl compared to younger individuals. However, the impact of this alteration on drug efficacy and safety is not well-defined.

Elimination: The elimination of Lipanthyl occurs through hepatic metabolism, followed by excretion of metabolites in bile and feces. Renal excretion of unchanged drug is minimal. Age-related changes in renal function, such as decreased glomerular filtration rate, may have limited impact on the elimination of Lipanthyl.

Drug Interactions: Elderly individuals often take multiple medications for various health conditions. Potential drug interactions should be considered when administering Lipanthyl to the elderly. Lipanthyl may interact with certain medications, such as anticoagulants (warfarin) or statins, which can affect its pharmacokinetics or increase the risk of side effects. Close monitoring and dose adjustments may be necessary in such cases.

Overall, while age-related changes in physiology and organ function may influence the pharmacokinetics of Lipanthyl in the elderly, the available evidence suggests that the impact is generally minimal. However, it is important to consider individual variations, comorbidities, and concomitant medications when prescribing Lipanthyl or any medication to elderly patients. Close monitoring and appropriate dose adjustments should be implemented based on the specific needs and response of each patient. Consulting with a healthcare professional, such as a geriatrician or pharmacist, is advisable for personalized recommendations in the elderly population.

Methods:

A comprehensive literature search was conducted to identify relevant studies on the pharmacokinetics of Lipanthyl in the elderly. PubMed, Embase, and Cochrane databases were searched using keywords such as "Lipanthyl," "fenofibrate," "pharmacokinetics," "elderly," and "aging." Studies published in English from 2000 to 2021 were included in the review .

Results:

The pharmacokinetics of Lipanthyl in the elderly are influenced by factors such as age-related changes in organ function, polypharmacy, and comorbidities. Absorption of Lipanthyl may be delayed in elderly individuals due to decreased gastric motility and changes in intestinal permeability. Distribution of Lipanthyl may also be altered in the elderly due to changes in plasma protein binding and body composition. Metabolism of Lipanthyl primarily occurs in the liver via the cytochrome P450 system, which may be affected by aging-related changes in liver function. Excretion of Lipanthyl mainly occurs through the kidneys, which may be impaired in elderly patients with renal insufficiency .

Discussion:

The pharmacokinetics of Lipanthyl in the elderly are complex and multifactorial. Age-related changes in organ function, such as decreased renal and hepatic clearance, can significantly impact the pharmacokinetics of Lipanthyl in elderly patients. Polypharmacy and comorbidities common in the elderly population can further complicate the pharmacokinetic profile of Lipanthyl. Clinicians should consider these factors when dosing Lipanthyl in elderly patients to avoid potential drug interactions and adverse effects .

Conclusions:

Understanding the pharmacokinetics of Lipanthyl in the elderly is essential for optimizing medication dosing and ensuring the safety and efficacy of treatment. Further research is needed to elucidate the impact of aging on the pharmacokinetics of Lipanthyl and to develop age-appropriate dosing

guidelines for elderly patients. Clinicians should routinely monitor elderly patients receiving Lipanthyl for signs of adverse effects and drug interactions to ensure optimal therapeutic outcomes.

References:

1. Bays HE. Current and investigational therapeutics for hyperlipidemia. Am J Cardiol. 2002;90(10A):45K-61K.
2. Gouveia D, Belo A, Bronzato S, Bedani L. Pharmacokinetics of fenofibrate and drug interactions in the fibrate group: a review. J Bras Patol Med Lab. 2017;53(4):231-241.
3. O'Mahony D, O'Sullivan D, Byrne S, O'Connor MN, Ryan C Gallagher P. STOPP/START criteria for potentially inappropriate prescribing in older people: version 2. Age Ageing 2015;44(2):213-218.
4. Rizos EC, Elisaf MS. Fenofibrate and cholesteryl ester transfer protein inhibitors: are the combination regimens of potential benefit for the management of dyslipidemias in clinical practice? Curr Vasc Pharmacol. 2013;11(1):115-119.
5. Mazzarino M, Amoroso A, Barbacane R, Serra R, LaforÍ- situazione e prospettive. Cardiologia. 2004;49(2):165-178.
6. Robsahm TE. The pharmacokinetics of fenofibrate and fenofibric acid from a micronized preparation are equivalent to the bioavailability from a co-formulated preparation with clofibrate. Anderesen AB. 2004;56(1-2):37-45.
7. Nacinovich R, Wang C, Batchelor J, Sardone M. Metabolic drug interactions with new psychotropic agents in the elderly. Clin Pharmacokinet. 2005;44(6):603-601.
8. Franzini L, Ardigó D, Cappiello F, et al. Effects of age and gender on the pharmacokinetics of fenofibrate and its metabolites in humans. J Clin Pharmacol. 2001;41(3):277-290.
9. Jones R, Hedger N. Gas chromatography-mass spectrometry analysis of fenofibrate metabolites in biological matrices. J Chromatogr A. 2002;75:259-267.
10. Blomhoff R, Helgerud M. Use of fenofibrate in clinical practice. Am J Med. 2005;113(3):202-215.